Can a med spa in Minnesota offer compounded semaglutide or tirzepatide?
Intake · part of The Practice Perimeter
Short answer
Yes — but only patient-specific: compounding must be done pursuant to a prescription drug order for an identified individual patient, unless otherwise permitted by the pharmacy chapter or board rules; stocking generic compounded vials is not that.
⚠️ compounded semaglutide is patient-specific by definition in Minnesota. “Compounding” means preparing, mixing, assembling, packaging, and labeling a drug for an identified individual patient as a result of a practitioner’s prescription drug order — and the definition closes with the general rule: “All compounding, regardless of the type of product, must be done pursuant to a prescription drug order unless otherwise permitted in this chapter or by the rules of the board.” A med spa cannot lawfully stock generic compounded vials against future demand.
Minn. Stat. § 151.01, subd. 35 · verified Sep 2, 2026 · regulatory monitoring, not legal advice
Related Minnesota rules
The one exception is narrow and named. “Anticipatory compounding” for a practitioner means “the preparation of a supply of a compounded drug product that is sufficient to meet the practitioner’s short-term anticipated need for dispensing or administering the drug to patients treated by the practitioner.” ⚠️ and it is not a supply channel: “anticipatory compounding is not the preparation of a compounded drug product for wholesale distribution.” Short-term, own patients, never for resale onward.
Minn. Stat. § 151.01, subd. 36 · verified Sep 2, 2026
⚠️ the rule, and it voids the prescription rather than merely exposing the prescriber. “a prescription drug order for the following drugs IS NOT VALID, unless it can be established that the prescription drug order was based on a documented patient evaluation, including an examination, adequate to establish a diagnosis and identify underlying conditions and contraindications to treatment.” The list is closed: controlled substances under § 152.02, board-defined controlled substances, muscle relaxants, centrally acting analgesics with opioid activity, drugs containing butalbital, and PDE5 inhibitors used to treat erectile dysfunction.
Minn. Stat. § 151.37, subd. 2(d) · verified Sep 2, 2026
How other states answer this
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Related Minnesota questions
- Is an exam required before a patient can be treated in Minnesota?
- Can the pre-treatment exam be done by telehealth in Minnesota?
Get Minnesota changes as they publish
We scan the Minnesota legislature and licensing boards daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.
Free · unsubscribe in one click · we never sell your address
← All Minnesota rules and changes · MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director. Legislative data via LegiScan (CC BY 4.0).